Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease

Transplantation

Volumn 65, Issue 7, 1998, Pages 979-988

  Imami, Nesrina ^a   Brookes, Paul A ^a   Lombardi, Giovanna ^a   Hakooz, Basma ^a   Johns, Michael ^a   Goldman, John M ^b   Batchelor, J Richard ^a   Lechler, Robert I ^a   Ritter, Mary A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4;

ANIMAL CELL; ARTICLE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HLA ANTIGENS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; RISK FACTORS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0032522688     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199804150-00019     Document Type: Article

References (52)

1. Vallera DA, Soderling CC, Carlson GJ, Kersey JH. Bone marrow transplantation across major histocompatibility barriers in mice: effects of elimination of T cells from donor grafts by treatment with monoclonal Thy-1.2 plus complement or antibody alone. Transplantation 1981; 31: 218.
2. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983; i: 612.
3. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985; 313: 765.
4. Storb R, Buckner CD. Human bone marrow transplantation. Eur J Clin Invest 1990; 20: 119.
5. Aversa F, Tabilio A, Terenzi A, et al. Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948.
6. Hale G, Waldmann H. CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15.
7. IrIe C, D'Amaro J, Van Rood JJ. Bone marrow transplantation from other than non-identical siblings. Bone Marrow Transplant 1988; 3 (suppl 1): 37.
8. Hows JM, Yin JL, Marsh J, et al. Histocompatible unrelated volunteer donors compared with HLA nonidentical family donors in marrow transplantation for aplastic anaemia and leukemia. Blood 1986; 68: 1322.
9. DeGast GC, Mickelson EM, Beatty PG, et al. Mixed leukocyte culture reactivity and graft-versus-host disease in HLA-identical marrow transplantation for leukaemia. Bone Marrow Transplant 1992; 9: 87.
10. Sharrock CEM, Man S, Wanachiwanawin W, Batchelor JR. Analysis of the alloreactive T cell repertoire in man: I. Differences in precursor frequency for cytotoxic T cell responses against allogeneic MHC molecules in unrelated individuals. Transplantation 1987; 43: 699.
11. Deacock S, Schwarer A, Batchelor R, Goldman J, Lechler R. A rapid limiting dilution assay for measuring frequencies of alloreactive, interleukin-2-producing T cells in humans. J Immunol Methods 1992; 147: 83.
12. Schwarer AP, Jiang YZ, Deacock S, et al. Comparison of helper and cytotoxic antirecipient T cell frequencies in unrelated bone marrow transplantation. Transplantation 1994; 58: 1198.
13. Mowat A. Antibodies to IFN-gamma prevent immunological mediated intestinal damage in murine graft-versus-host reactions. Immunology 1989; 68: 18.
14. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405.
15. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE. Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sub-lethally irradiated mice. Blood 1994; 84: 3540.
16. Kregner W, Snyder KM, Byon JCH, Falzarno G, Ferrara JLM. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585.
17. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422.
18. Imami N, Larché M, Ritter MA. Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4- producing human T cells. Int Immunol 1994; 6: 1575.
19. Hu-Li J, Ohara J, Watson C, Tsang W, Paul WE. Derivation of a T cell line that is highly responsive to IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant of that line (CT.4S). J Immunol 1989; 142: 800.
20. Russell SM, Keegan AD, Harada N, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 1993; 262: 1880.
21. Yang SY, Milford E, Hammerling U, Dupont B. Description of the reference panel of B-lymphoblastoid cell lines for factors of the HLA system: the B-cell line panel designed for the tenth International Histocompatibility Workshop. In: Dupont B, ed. Immunobiology of HLA. Vol. I. Histocompatibility testing 1987. New York: Springer-Verlag, 1989: 11.
22. Hornick PI, Brookes PA, Mason PD, et al. Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2 producing alloreactive T helper lymphocytes. Transplantation 1997; 64: 472.
23. Bidwell JL, Bidwell EA, Savage DA, Middleton D, Klouda PT, Bradley BA. A DNA-RFLP typing system that positively identifies serologically well-defined and ill-defined HLA-DR and DQ alleles, including DRw10. Transplantation 1988; 45: 640.
24. Yang SY. A standardization method for detection of HLA-A and HLA-B alleles by one-dimensional isoelectric focusing (IEF) gel electrophoresis. In: Dupont B, ed. Immunobiology of HLA. New York: Springer-Verlag, 1989: 332.
25. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225. Comment. Tissue Antigens 1993; 41: 55.
26. Olerup O, Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225. Comment. Tissue Antigens 1993; 41: 55.
27. Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens 1993; 41: 119.
28. Fazekas de St. Groth S. The evaluation of limiting dilution assays. J Immunol Methods 1982; 49: R11.
29. Lombardi G, Sidhu S, Dodi T, Batchelor R, Lechler R. Failure of correlation between B7 expression and activation of interleukin-2-secreting T cells. Eur J Immunol 1994; 24: 523.
30. Kaminski E, Hows J, Man S, et al. Prediction of graft versus host disease by frequency analysis of cytotoxic T cells after unrelated donor bone marrow transplantation. Transplantation 1989; 48: 608.
31. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1976; 53: 457.
32. Mason PD, Robinson C, Lechler RI. Detection of donor-specific hyporesponsiveness following late failure of human renal allografts. Kidney Int 1996; 50: 1019.
33. Reisaeter AV, Thorsby E, Brinchmann JL. Analysis of alloreactive helper T lymphocyte precursor frequencies: influence of interleukin-2 produced by the stimulating cells. J Immunol Methods 1996; 189: 65.
34. Schwarer AP, Bridge J, Kaminski E, Batchelor JR, Goldman JM, Lechler RI. Alloreactive helper T-lymphocyte precursor frequencies in the peripheral blood of genotypic HLA-matched sibling and phenotypically HLA-matched unrelated donors: a functional assay predicting acute GVHD and survival after BMT. Blood 1991; 78 (suppl 1): 188a.
35. Schwarer AP, Jiang YZ, Brookes PA. et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203.
36. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med 1992; 327: 1613.
37. Theobald M. Predicting graft-versus-host disease. Curr Opin Immunol 1995; 7: 649.
38. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787.
39. Kregner W, Snyder KM, Byon JCH, Falzarno G, Ferrara JLM. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585.
40. Cua DJ, Coffman RL, Stohlman SA. Exposure to T helper 2 cytokines in vivo before encounter with antigen selects for T helper subsets via alterations in antigen-presenting cell function. J Immunol 1996; 157: 2830.
41. Turner DM, Grant SC, Lamb WR, et al. A genetic marker of high TNF-α production in heart transplant recipients. Transplantation 1995; 60: 1113.
42. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138.
43. pos T cells promptly produce interleukin 4 in response to In vivo challenge with anti-CD3. J Exp Med 1994; 179: 1285.
44. Coffman RL, von der Weid T. Multiple pathways for the initiation of T helper 2 (Th2) responses. J Exp Med 1997; 185: 373.
45. Spencer A, Szydlo RM, Brookes PA, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vitro T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995; 86: 3590.
46. Sykes M. Novel approaches to the control of graft versus host disease. Curr Opin Immunol 1993; 5: 774.
47. Waldmann H, Cobbold S, Hale G. What can be done to prevent graft versus host disease? Cur Opin Immunol 1994; 6: 777.
48. Herrera C, Martin C, Garcie-Castellano JM, et al. Prevention of GVHD by selective CD4+ T cell depletion plus adjustment of the CD8+ cell content in donor bone marrow. Blood 1995; 86: 571a.
49. Nimer SD, Giorgi J, Gajewski JL, et al. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. Transplantation 1994; 57: 82.
50. Mackinnon S, Papadoponlos EB, Carabsi M, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of CML after bone marrow transplantation: separation of graft versus leukemia responses from graft versus host disease. Blood 1995; 86: 1261.
51. Barrett AJ, Couriel D, Dunbar CE, et al. Low incidence of acute GVHD following delayed T-cell add-back after T-depleted BMT for hematological malignancies. Blood 1995; 86: 619a.
52. Ferrara JLM. Cytokine dysregulation as a mechanism of graft versus host disease. Curr Opin Immunol 1993; 5: 794.